863031-21-4 | Azilsartan medoxomil

disodium2-ethoxy-1-2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-ylmethyl}-1H-benzimidazole-7-carboxylate 

  80841-78-7    863031-21-4 

[1]Patent:US2005/187269,2005,A1.Locationinpatent:Page/Pagecolumn12-13

91526-18-0    147403-03-0    863031-21-4 

[1]Patent:US2005/187269,2005,A1.Locationinpatent:Page/Pagecolumn14

[2]Patent:WO2012/107814,2012,A1.Locationinpatent:Page/Pagecolumn15-16

[3]Patent:WO2013/156005,2013,A1.Locationinpatent:Page/Pagecolumn10

[4]Patent:WO2014/48404,2014,A1.Locationinpatent:Page/Pagecolumn8-9

[5]OrganicProcessResearchandDevelopment,2013,vol.17,p.77-86

[6]Patent:WO2014/33740,2014,A1.Locationinpatent:Page/Pagecolumn12-13

[7]Patent:WO2014/49512,2014,A2.Locationinpatent:Page/Pagecolumn9

[8]Patent:US2015/183767,2015,A1.Locationinpatent:Paragraph0148

C32H21Cl3N4O6 

  91526-18-0    863031-21-4 

[1]Patent:US2005/187269,2005,A1.Locationinpatent:Page/Pagecolumn13

863031-21-4   

(5-methyl-2-oxo-1,3-dioxol-4-yl)methyl2-ethoxy-1-2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-ylmethyl}-1H-benzimidazole-7-carboxylatesodiumsalt 

[1]Patent:US2005/187269,2005,A1.Locationinpatent:Page/Pagecolumn13-14

863031-21-4   

1-{2’-(2,5-dihydro-5-oxo-1,2,4-oxodiazol-3-yl)(1,1’-biphenyl)-4-yl}methyl-2-ethoxy-1H-benzimidazole-7-carboxylicacid(5-methyl-2-oxo-1,3-dioxol-4-yl)methylesterpotassiumsalt 

[1]OrganicProcessResearchandDevelopment,2015,vol.19,p.514-519

[2]Patent:US2005/187269,2005,A1.Locationinpatent:Page/Pagecolumn13

[3]Patent:WO2012/107814,2012,A1.Locationinpatent:Page/Pagecolumn17

[4]Patent:WO2013/104342,2013,A1.Locationinpatent:Page/Pagecolumn15

[5]Patent:WO2013/114305,2013,A1.Locationinpatent:Page/Pagecolumn24;25

[6]Patent:WO2014/20381,2014,A1.Locationinpatent:Paragraph34

[7]Patent:WO2014/9969,2014,A2.Locationinpatent:Page/Pagecolumn9

[8]Patent:WO2014/33740,2014,A1.Locationinpatent:Page/Pagecolumn16-17

[9]Patent:US2015/11774,2015,A1.Locationinpatent:Paragraph0109;0110;0111

[10]Patent:CN108358907,2018,A.Locationinpatent:Paragraph0061;0063

Title: Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists.

Journal: American journal of therapeutics 20140101

Title: Azilsartan medoxomil: a review of its use in hypertension.

Journal: Clinical drug investigation 20120901

Title: [Azilsartan: a new angiotensin receptor blocker].

Journal: Nihon rinsho. Japanese journal of clinical medicine 20120901

Title: Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension.

Journal: Hypertension (Dallas, Tex. : 1979) 20120801

Title: Assessment of the environmental fate and effects of azilsartan, a selective antagonist of angiotensin II type 1.

Journal: Chemosphere 20120601

Title: [In vitro and in vivo pharmacological profiles of a novel angiotensin type 1-receptor blocker, azilsartan].

Journal: Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20120601

Title: Comparison of the efficacy and safety of azilsartan with that of candesartan cilexetil in Japanese patients with grade I-II essential hypertension: a randomized, double-blind clinical study.

Journal: Hypertension research : official journal of the Japanese Society of Hypertension 20120501

Title: Blood pressure-lowering efficacy of the fixed-dose combination of azilsartan medoxomil and chlorthalidone: a factorial study.

Journal: Journal of clinical hypertension (Greenwich, Conn.) 20120501

Title: Edarbyclor: an ARB/chlorthalidone combination for hypertension.

Journal: The Medical letter on drugs and therapeutics 20120305

Title: New drugs 2012 part I.

Journal: Nursing 20120301

Title: How full is our antihypertensives pipeline?

Journal: Journal of pharmacology & pharmacotherapeutics 20120101

Title: Differential pharmacology and benefit/risk of azilsartan compared to other sartans.

Journal: Vascular health and risk management 20120101

Title: New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil.

Journal: Integrated blood pressure control 20120101

Title: What is a preferred angiotensin II receptor blocker-based combination therapy for blood pressure control in hypertensive patients with diabetic and non-diabetic renal impairment?

Journal: Cardiovascular diabetology 20120101

Title: Out-of-office blood pressure: from measurement to control.

Journal: Integrated blood pressure control 20120101

Title: Critical evaluation of the efficacy and tolerability of azilsartan.

Journal: Vascular health and risk management 20120101

Title: Clinical utility of azilsartan-chlorthalidone fixed combination in the management of hypertension.

Journal: Vascular health and risk management 20120101

Title: Azilsartan treatment improves insulin sensitivity in obese spontaneously hypertensive Koletsky rats.

Journal: Diabetes, obesity & metabolism 20111201

Title: Molecular and cellular effects of azilsartan: a new generation angiotensin II receptor blocker.

Journal: Journal of hypertension 20111201

Title: Azilsartan medoxomil: a new angiotensin II receptor antagonist for treatment of hypertension.

Journal: The Annals of pharmacotherapy 20111201

Title: Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.

Journal: European journal of pharmacology 20111101

Title: Azilsartan medoxomil: a new Angiotensin receptor blocker.

Journal: Clinical therapeutics 20111101

Title: Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker.

Journal: P & T : a peer-reviewed journal for formulary management 20111001

Title: Azilsartan medoxomil for the treatment of hypertension.

Journal: Drugs of today (Barcelona, Spain : 1998) 20110901

Title: The angiotensin receptor blocker, azilsartan medoxomil (TAK-491), suppresses vascular wall expression of plasminogen activator inhibitor type-I protein potentially facilitating the stabilization of atherosclerotic plaques.

Journal: Journal of cardiovascular pharmacology 20110801

Title: Comparison of the novel angiotensin II receptor blocker azilsartan medoxomil vs valsartan by ambulatory blood pressure monitoring.

Journal: Journal of clinical hypertension (Greenwich, Conn.) 20110701

Title: Azilsartan medoxomil (Edarbi) the eighth ARB.

Journal: The Medical letter on drugs and therapeutics 20110516

Title: New angiotensin-receptor blocker approved by FDA.

Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20110401

Title: In vitro antagonistic properties of a new angiotensin type 1 receptor blocker, azilsartan, in receptor binding and function studies.

Journal: The Journal of pharmacology and experimental therapeutics 20110301

Title: Effects of the angiotensin receptor blocker azilsartan medoxomil versus olmesartan and valsartan on ambulatory and clinic blood pressure in patients with stages 1 and 2 hypertension.

Journal: Hypertension (Dallas, Tex. : 1979) 20110301

Title: The comparative effects of azilsartan medoxomil and olmesartan on ambulatory and clinic blood pressure.

Journal: Journal of clinical hypertension (Greenwich, Conn.) 20110201

Title: New drugs. Azilsartan medoxomil, belimumab, and lurasidone hydrochloride.

Journal: Journal of the American Pharmacists Association : JAPhA 20110101

Title: Azilsartan: a newly approved angiotensin II receptor blocker.

Journal: Cardiology in review 20110101

Title: Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk.

Journal: Vascular health and risk management 20110101

Title: Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination.

Journal: Integrated blood pressure control 20110101